A Phase I/II Study of Pazopanib in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme After Surgery and RT-CT
Phase of Trial: Phase I/II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Pazopanib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms PAZOGLIO
- 10 Jun 2017 Biomarkers information updated
- 21 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 21 Feb 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.